Bioventus (BVS)
(Delayed Data from NSDQ)
$7.17 USD
+0.10 (1.41%)
Updated Jul 19, 2024 04:00 PM ET
After-Market: $7.16 -0.01 (-0.14%) 7:58 PM ET
2-Buy of 5 2
B Value C Growth D Momentum C VGM
Price, Consensus and EPS Surprise
BVS 7.17 +0.10(1.41%)
Will BVS be a Portfolio Killer in July?
Zacks Investment Research is releasing its prediction for BVS based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for BVS
Merck (MRK) Gets Exclusive Rights to Opevesostat From Partner
Encompass Health (EHC) Expands in Louisville With New Rehab Unit
BVS: What are Zacks experts saying now?
Zacks Private Portfolio Services
Here's Why Investors Must Hold on to Centene (CNC) Stock Now
Compelling Reasons to Hold on to Cigna (CI) Stock for Now
Here's Why You Should Consider Buying Bioventus (BVS) Stock
Other News for BVS
Wilsons Reaffirms Their Buy Rating on Bravura Solutions Limited (BVS)
Envoy Medical appoints Michael Crowe to board of directors
Bravura Joins S&P/ASX Tech Index in June Rebalance
3 Stocks Under $10 With Mammoth Growth Prospects
Bioventus management to meet with Craig Hallum